Member Info for tqhussain

I havent sold yet. My finger has gone over the sell button several times, but only holding back due to the results end of month. If they aint good im gone.

results are out on 30th june. Do i sell now or wait hummmm

Excellent results.

I am out of this ****e with a 40% loss

down and down :(

http://citywire.co.uk/personal/-/news/markets-companies-and-funds/content.aspx?ID=404007

lol, http://www.topnews.in/ed-might-be-cured-10-minutes-thru-inhaler-2262231

Crap share, wasted a year in this and down 35%

Ive just had a look to see if any news out there, but nothing. It is Certainly of interest to see barclays take a positioning. 8% stake is pretty big considering the state STBR have been in, i can only presume that they have some insight in to STBR's near future (T/O?). Will keep an eye out for any other information.

http://www.thepharmaletter.com/file/94825/sosei-and-vectura-get-75-million-milestone-each-as-novartis-starts-ph-iii-study-with-qva149-and-nva237.html

* Triggers $7.5 mln payment to British company * Vectura sees 25 pct rise in year revenue, narrowed loss (Adds detail) LONDON, May 10 (Reuters) - Vectura (VEC.L) said on Monday its Swiss partner Novartis (NOVN.VX) had started final-stage trials of a combination lung drug, triggering a $7.5 million milestone payment for the British company. The drug QVA149 -- which combines Vectura's "smoker's lung" drug NVA237 with Novartis's QAB149, or indacaterol -- had been expected to enter Phase III in the fourth quarter of last year, but was delayed by U.S. regulators wanting information on the dosing proposed for indacaterol. Following the delay, Novartis said it did not expect to file QVA149 for regulatory approval in chronic obstructive pulmonary disease before 2012. It had previously targeted 2011. Phase III trials with NVA237 on its own commenced in June 2009, and Novartis expected to file for approval in 2011, Vectura said. In a trading update, also on Monday, Vectura said its revenue grew by more than 25 percent in the year to end March -- to 38-42 million pounds -- and its after-tax loss would be significantly reduced on the 16.7 million pounds ($25.83 million) in 2009. (Reporting by Paul Sandle; Editing by Victoria Bryan) ($1=.6465 Pound) Another 12 months and this should be going places!

Questions i posted to VEC

I have a couple of questions I would like ask; First, when do you expect the results for the NVA237 phase 3 trials. Secondly, Are your looking for another partner for the VR315 (US), if not, are you looking to go at it alone and push the product in to the US market. I would appreciate your reply. Response; NVA237 is licensed to Novartis and they are responsible for the development programme. They have not disclosed when they expect the Phase III data - only that they expect to file for approval in 2011. With regard to the US VR315 development, we are planning on taking this forward ourselves and will market it ourselves in certain territories targeting high prescribers; but will partner for other territories. P.s. got a reply within an hour of sending the email, thats what i call a good service!

i have just doubled my holding and averaged down

Just want your opinion, do you see the management team pulling this one back. I have been thinking of buying but not too sure as i feel STBR could go bust!

well, yesterday morning was the best time, but 40p is a very good entry price.

52 Week Low 53.50p. Going off memory, i think it was around the 56p mark, could be a few pennis off.

will keep an eye on it until i can free up some funds!

I am fairly new to shares, been trading for just about a year. I have been following HCL since last year. I will look for a good entry price, since SP has been on a downward trend.

but the result were not that good, they were ok. Plus, i dont remeber if there was any dividend. I think once they do give dividend then we will see good rises in the SP.